Home Prescription Drugs Tags

View the Latest: Prescription Drugs

Filter

List Grid

241 - 250 of 798 Results

  • Allowing Medicare to Negotiate Drug Prices Remains Broadly Popular Among Voters, Though Most Are Unaware of the Law and Its Projected Savings

    News Release

    Allowing Medicare to negotiate drug prices on behalf of older Americans remains broadly popular across partisans, though many voters are unaware of the new law and the billions of dollars it is expected to save in 2026, a new KFF Health Tracking Poll finds.A large majority (85%) of voters say they support allowing the federal government to negotiate the price of some prescription drugs for people with Medicare. This includes at least three quarters of…

  • ADAP Issue Brief: AIDS Drug Assistance Programs – Getting the Best Price?

    Issue Brief

    This issue brief, prepared as part of the National ADAP Monitoring Project, examines how ADAPs purchase and dispense drugs, and the drug discount programs that assist states in containing ADAP costs. For more information on the series see the National ADAP Monitoring Project page. Issue Brief

  • Medicare’s Disabled Beneficiaries: The Forgotten Population in the Debate Over Drug Benefits

    Report

    About 5 million Americans under age 65 qualify for Medicare coverage because they are totally and permanently disabled. They are more likely than the elderly to live in poverty, to be in poor health, and to experience difficulties living independently and performing basic daily tasks. A new study from The Commonwealth Fund and the Henry J. Kaiser Family Foundation, reports that the disabled have few options other than Medicaid for obtaining prescription coverage. In ,…

  • Medicare and Prescription Drug Spending Chartpack

    Report

    This chartpack provides 2003 and 2006 estimates of total and out-of-pocket prescription drug spending by Medicare beneficiaries. The data and analysis for this chartpack, prepared by Actuarial Research Corporation, assume no change in current law. Chart Pack

  • National ADAP Monitoring Project: Annual Report, April 2002

    Report

    This report, the sixth in an annual series, provides an overview of the status of state-administered AIDS Drug Assistance Programs (ADAPs) and documents how these programs are responding to the changing fiscal, clinical and epidemiological dynamics of HIV/AIDS. ADAPs, authorized under Title II of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, provide HIV/AIDS-related prescription drugs to uninsured and underinsured individuals living with HIV/AIDS in the 50 states, the District of Columbia, Puerto Rico,…

  • Analysis of Medicare Prescription Drug Plans In 2012 And Key Trends Since 2006

    Report

    This report presents findings from an analysis of the Medicare Part D marketplace in 2012 and changes in drug coverage and costs since 2006. It presents key findings related to Medicare drug plan plan availability, premiums, cost-sharing, the coverage gap and availability for low-income beneficiaries, the coverage gap, benefit design and cost sharing, formularies, and utilization management, based on data from CMS for all plans participating in Part D. The analysis was conducted jointly by…

  • How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices?

    Issue Brief

    A class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment. A new analysis compares list prices for semaglutide—including Ozempic, which has been approved in the U.S. for diabetes, and Wegovy, which has the same active ingredient and has been approved for weight…

  • The 4 Arguments You Will Hear Against Drug Price Negotiation

    Perspective

    As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF's Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.

  • Medicare Part D: A First Look at Medicare Drug Plans in 2023

    Issue Brief

    This issue brief provides an overview of the Medicare Part D marketplace in 2023 and key trends over time, focusing primarily on stand-alone Medicare drug plans, including plan availability, premiums, and cost sharing. The brief also describes the prescription drug provisions in the Inflation Reduction Act of 2022 that affect the Medicare Part D marketplace beginning in 2023

  • Most Women are in Favor of Making Birth Control Pills Available Over the Counter without a Prescription if Research Shows they are Safe and Effective

    News Release

    A new KFF survey finds that more than three-quarters (77%) of females ages 18-49 favor making birth control pills available without a doctor’s prescription if research shows they are safe and effective. Among those who favor making birth control pills available over the counter and who currently use prescription oral contraception, 60% say they would be likely to use over-the-counter birth control pills. Most say the main reason is convenience (59%). Many females who would…